Watch this video to learn more about the process for manufacturing biosimilars
The health information contained herein is provided for informational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. This information is intended only for residents of the United States.
This video is intended to be viewed within the context of its original location online. Pfizer is not responsible for the content if viewed elsewhere.
PFIZER STANDARDS at work
State-of-the-art analytical tools help Pfizer Biosimilars development teams establish that the biosimilar products they develop match the reference products with a high degree of similarity.
- This level of control and surveillance is essential because Pfizer is working with living cells to create very complex molecules
- Because small changes—such as pressure and temperature environment—in the raw materials used for the processing conditions can affect the structure and function of the end product, precision is essential
EXPANSIVE FOOTPRINT
Pfizer is committed to high standards for quality and compliance, with fast, flexible solutions across the manufacturing and supply-chain spectrum.
39
manufacturing facilities
~28,000
manufacturing colleagues
>25 billion
doses of medications produced per year
As of May 2022.
Commitment to quality
Pfizer’s culture of quality forms the foundation for excellence in manufacturing biosimilars at Pfizer and supplier sites.
- Rich history of innovation in manufacturing
- Quality-by-design principles for production
- Current Good Manufacturing Practice (CGMP) standards in quality control, supported by advanced technologies and scientific expertise
- State-of-the-art production
- Commitment to continuous improvement process
- Highly Orchestrated Supply Network (HOSuN)
